Agilent Technologies (A) said Thursday its PD-L1 IHC 22C3 pharmDx assay has received European In Vitro Diagnostic Regulation certification for use as a companion diagnostic to identify gastric or gastroesophageal junction adenocarcinoma patients who may be treated with Merck's (MRK) Keytruda.
The company said PD-L1 IHC 22C3 pharmDx assay is now IVDR certified as an aid in seven cancer indications for treatment with Keytruda.
Agilent said it developed the test in partnership with Merck, which developed Keytruda.
Price: 102.37, Change: -0.34, Percent Change: -0.33
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。